|
Malignant tumor of cervix
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The purpose of this study was to investigate the value of combinatorial assay of plasma CADM1 promoter hypermethylation and D-dimer as a metastasis marker in CC.
|
30945386 |
2019 |
|
Malignant tumor of cervix
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Two hundred and sixty samples with available frozen cell pellets including 70 randomly selected cases of negative for intraepithelial lesion or malignancy (NILM)&HPV-negative, 70 randomly selected cases of NILM&HPV-positive, and 120 cytologic abnormalities & HPV-positive from a population-based cervical cancer screening program (n = 7,604) were investigated for the DNA methylation pattern of CADM1, FAM19A4, and MAL.
|
30608989 |
2019 |
|
Malignant tumor of cervix
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
CADM1/MAL methylation status in cervical scrapes appears to be representative of the worst underlying lesion, particularly for CIN3 and cervical cancer.
|
26219541 |
2016 |
|
Malignant tumor of cervix
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have shown that CADM1/MAL-methylation testing detects high-grade CIN lesions with a high short-term progression risk for cervical cancer.
|
27430395 |
2016 |
|
Malignant tumor of cervix
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among human cervical neoplastic cells, the methylation indices of ADCYAP1 were 7.8 (95% confidence interval [95% CI], 7.0-8.6) in subjects with LSILs and 39.8 (95% CI, 29.0-54.7) in those with cervical cancer (P < 0.001); for PAX1, 7.2 (95% CI, 6.1-8.5) and 37.8 (95% CI, 27.1-52.7), respectively; for CADM1, 3.5 (95% CI, 3.0-4.0) and 17.7 (95% CI, 10.8-29.1), respectively; for MAL, 2.7 (95% CI, 2.5-3.0) and 13.0 (95% CI, 7.6-22.0), respectively (P < 0.001 for each).
|
26552048 |
2016 |
|
Malignant tumor of cervix
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate that epigenetic alteration of CADM1 was more frequent in HPV-positive cervical cancers and that restoration of CADM1 expression may be a potential strategy for cervical cancer therapy.
|
25845528 |
2015 |
|
Malignant tumor of cervix
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Here, CADM1 and MAL DNA methylation levels were analysed in cervical scrapes of hrHPV-positive women with no underlying high-grade disease, high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer.
|
23456988 |
2013 |
|
Malignant tumor of cervix
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we determined the extent of CADM1 promoter methylation in cervical (pre)malignant lesions and its relation to anchorage-independent growth and gene silencing to select a CADM1-based methylation marker for identification of women at risk of cervical cancer.
|
18498117 |
2008 |
|
Malignant tumor of cervix
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation maps of the IGSF4 promoter region were generated for 11 CC cell lines based upon bisulfite-genomic sequencing, using seven nested-PCR primer sets covering 97 CpG sites.
|
15589594 |
2005 |
|
Malignant tumor of cervix
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia.
|
14970278 |
2004 |